Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: MISCELLANEOUS

Braingrid Limited Provides Update On COVID-19 and Announces Request for Extension to File Interim Financial Statements and Management's Discussion and Analysis


TORONTO, July 02, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) ("Braingrid") wishes to provide an update on the COVID-19 pandemic as it affects Braingrid and the status of the filing of its interim financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications, for the interim period ended April 30, 2020.

The COVID-19 pandemic is creating unprecedented challenges to the global economy and stock markets. Braingrid's Board of Directors and Management are taking all necessary precautions to ensure the health of its employees and best manage the short-term challenges to the business.

On March 18, 2020, the Canadian Securities Administrators ("CSA") issued a notice stating that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made on or prior to June 1, 2020 as a result of the COVID-19 pandemic. As such the Ontario Securities Commission ("OSC") has enacted Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements (the "OSC Temporary Exemption"). Braingrid will be relying on this extension period due to delays experienced as result of the COVID-19 pandemic.

Braingrid will be relying on the OSC Temporary Exemption in respect to the following provisions:

Braingrid is continuing to work diligently and expeditiously with its auditors to file the Interim Filings on or before August 13, 2020. In the interim, management and other insiders of Braingrid are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207, Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions. Braingrid confirms that since the filing of its interim consolidated financial statements for the period ended October 31, 2019, there have been no material business developments other than those disclosed through news releases.

Additional information regarding Braingrid is available on SEDAR www.sedar.com.

About Braingrid:

Braingrid is a global technology company committed to the best interests of the precision agriculture industry for the long term. We provide valuable grow analytics by capturing real-time data using our technology platform to increase revenues, reduce costs, risks and improve yield - making it easier for the grower to operate efficiently and effectively. Braingrid is listed on the CSE under the symbol BGRD.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Media Contact:

Braingrid Limited
Doug Harris
Chief Financial Officer
416-480-2488
[email protected]
www.braingrid.io


These press releases may also interest you

at 22:16
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...



News published on and distributed by: